The Wisconsin Alumni Research Foundation (WARF) and Ginkgo Bioworks Inc. have announced a partnership to leverage Ginkgo's proprietary high-throughput combinatorial chimeric antigen receptor (CAR) discovery and screening platform with the aim of discovering next-generation GD2 CAR T-cell therapies.
Pyramid Biosciences Inc. and Genequantum Healthcare (Suzhou) Co. Ltd. have entered into an exclusive license agreement to develop and commercialize GQ-1010, a potential best-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan).
Biotheryx Inc. has entered into a research collaboration and license agreement with Incyte Corp. to discover and develop targeted protein degraders for novel oncology targets.
Absci Corp. and M2gen have entered into a partnership to create new cancer medicines. Absci’s generative artificial intelligence drug creation platform will leverage M2gen’s clinical and molecular data set, ORIEN Avatar, to accelerate the creation of therapeutics for a range of malignancies and patient profiles.
Calyx (Perceptive Informatics LLC) has entered into a strategic partnership with Ceretype Neuromedicine Inc., whose novel functional magnetic resonance imaging (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies
Evergreen Discovery (Evergreen Theragnostics Inc.) and Orbit Discovery Ltd. have entered into a collaboration to identify specific cell-targeting peptides and advance the development of novel radiopharmaceuticals.
Immunoprecise Antibodies Ltd.'s Talem Therapeutics LLC subsidiary has entered into a research collaboration and exclusive option license agreement with Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas Pharma Inc.
RSS
